Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $192.89 USD
Change Today -8.74 / -4.33%
Volume 8.2M
PRGO On Other Exchanges
Symbol
Exchange
New York
Tel Aviv
Frankfurt
As of 8:04 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Treasury Building

Lower Grand Canal Street

Dublin, 2

Ireland

Phone: 353 1 709 4002

Fax:

Perrigo Company plc develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). The company operates through wholly owned subsidiaries. In the U.S., its operations are conducted primarily through L. Perrigo Company; Perrigo Company of South Carolina, Inc.; Perrigo New York, Inc.; PBM Products, LLC; PBM Nutritionals, LLC; Paddock Laboratories, LLC; Perrigo Diabetes Care, LLC; Sergeant's Pet Care Products, Inc.; and Fidopharm, Inc. Outside the U.S., its operations are conducted primarily through Elan Pharma International Limited; Perrigo Israel Pharmaceuticals Ltd.; Perrigo API Ltd.; Quimica y Farmacia S.A. de C.V.; Laboratorios Diba, S.A.; Wrafton Laboratories Limited; Galpharm Healthcare Ltd.; Orion Laboratories Pty Ltd; and Rosemont Pharmaceuticals Ltd. Segments The company has five segments: Consumer Healthcare, Nutritionals, Rx Pharmaceuticals, API, and Specialty Sciences. In addition, the company has an Other category that consists of the Israel Pharmaceutical and Diagnostic Products operating segment. Consumer Healthcare segment The Consumer Healthcare segment is a store brand marketer and manufacturer of OTC pharmaceutical products. Major product categories include analgesics, cough/cold/allergy/sinus, gastrointestinal, smoking cessation, animal health, and its secondary product categories include feminine hygiene, diabetes care and dermatological care. This segment markets approximately 2,800 store brand products, with 11,000 stock-keeping units (SKUs), to 1,100 customers. The company also manufactures and markets certain products under its Good Sense, Sergeant's, Sentry, Herron, and PetArmor brands. The company’s U.S.-based customers are major national and regional retail drug, supermarket and mass merchandise chains, including Walmart, CVS, Walgreens, Kroger, Target, Dollar General, Rite Aid, Sam’s Club, Costco, Petco and Petsmart; and major wholesalers, including McKesson, Cardinal Health and AmerisourceBergen. Competition: The company’s competitors in the U.S. Consumer Healthcare market are Dr. Reddy’s Laboratories, Ltd.; Actavis Inc.; Ranbaxy Inc.; PL Developments; Nipro Corporation; and LNK International, Inc. Nutritionals segment The Nutritionals segment develops, manufactures, markets and distributes store brand infant and toddler formula products, infant and toddler foods, and vitamin, mineral and dietary supplement (VMS) products to retailers, distributors and consumers primarily in the U.S., Canada, Mexico and China. The Nutritionals segment markets approximately 900 store brand products, with 3,400 SKUs, to 150 customers. The company’s U.S.-based customers are major national and regional retail drug, supermarket and mass merchandise chains, including Walmart, CVS, Walgreens, Kroger, Target, Sam’s Club and Costco, as well as major wholesalers, including McKesson. Competition: The company’s competitors for infant formula are Abbott Laboratories; Mead Johnson Nutrition Co.; Nestle S.A. (Gerber); and Danone Baby Nutrition. The company competes in the VMS category with publicly-traded and privately-owned companies, such as Bayer AG; Pfizer, Inc.; NBTY and Rexall Sundown, Inc.; and IVC, Inc. Rx Pharmaceuticals segment The Rx Pharmaceuticals segment develops, manufactures and markets a portfolio of generic prescription drugs primarily for the U.S. market. This portfolio encompasses an array of topical dosage forms such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions and powders. The portfolio also includes select controlled substances, injectables, hormones, oral solid dosage forms and oral liquid formulations. In addition, the Rx Pharmaceuticals segment offers OTC products through the prescription channel (referred to as ‘ORx’ marketing). ORx products are OTC products available for pharmacy fulfillment and healthcare reimbursement when prescribed by a physician. The company offers approximately 100 ORx products that are reimbursable through many health plans and Medicaid and Medicare programs.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRGO:US $192.89 USD -8.74

PRGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $93.27 USD -0.81
Hospira Inc $87.61 USD -0.05
Mead Johnson Nutrition Co $97.94 USD +1.53
Sigma-Aldrich Corp $139.00 USD +0.03
Sun Pharmaceutical Industries Ltd 947.40 INR 0.00
View Industry Companies
 

Industry Analysis

PRGO

Industry Average

Valuation PRGO Industry Range
Price/Earnings 100.0x
Price/Sales 6.7x
Price/Book 3.0x
Price/Cash Flow 139.6x
TEV/Sales 4.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERRIGO CO PLC, please visit www.perrigo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.